

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

PROVECTUS PHARMACEUTICALS INC
Form SC 13G/A
February 07, 2008

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)
Amendment No. 4

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2

Provectus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

74373-F-100

(CUSIP Number)

April 23, 2007

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

=====

CUSIP No.	74373-F-100	13G
-----------	-------------	-----

=====

1. NAME OF REPORTING PERSONS
S.S. NO. OF ABOVE PERSONS

Richard Smithline

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) <input type="checkbox"/>
	(b) <input checked="" type="checkbox"/>

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

1,117,333*

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6. SHARED VOTING POWER

0

7. SOLE DISPOSITIVE POWER

1,117,333*

8. SHARED DISPOSITIVE POWER

0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,117,333*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.23%*

12. TYPE OF REPORTING PERSON

IN

=====
CUSIP No. 74373-F-100 13G
=====

1. NAME OF REPORTING PERSONS
S.S. NO. OF ABOVE PERSONS

Centrecourt Asset Management LLC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

	5.	SOLE VOTING POWER	
			1,117,333*
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6.	SHARED VOTING POWER	0
	7.	SOLE DISPOSITIVE POWER	1,117,333*
	8.	SHARED DISPOSITIVE POWER	0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,117,333*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.23%*

12. TYPE OF REPORTING PERSON

IA

=====
CUSIP No. 74373-F-100 13G
=====

1. NAME OF REPORTING PERSONS
S.S. NO. OF ABOVE PERSONS

CAMOFI Master LDC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

	5.	SOLE VOTING POWER	
			1,117,333*
NUMBER OF SHARES	6.	SHARED VOTING POWER	

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 0

7. SOLE DISPOSITIVE POWER2 1,117,333*

8. SHARED DISPOSITIVE POWER 0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,117,333*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_ |

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.23%*

12. TYPE OF REPORTING PERSON OO

Item 1.

(a) Name of Issuer:

Provectus Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

7327 Oak Ridge Highway, Suite A
Knoxville, TN 37931

Item 2.

(a) Name of Person Filing:

This Schedule 13G is being filed with respect to shares of Common Stock of the Issuer which are beneficially owned by Richard Smithline ("Mr. Smithline"), Centrecourt Asset Management LLC ("Centrecourt") and CAMOFI Master LDC ("CAMOFI") (collectively, the "Reporting Persons").

The Reporting Persons are making a joint filing because they may be deemed a group pursuant to Section 13 of the Securities Exchange Act of 1934, as amended. The Reporting Persons do not affirm the existence of such a group.

(b) Address of Principal Business Office or, if none, Residence:

The principal business address of each of Mr. Smithline and Centrecourt is:

350 Madison Avenue, 8th Floor
New York, NY 10017

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

The principal business address of CAMOFI is:

90 Fort Street, 5th Floor
Box 32021 SMB
Grand Cayman, Cayman Islands

(c) Citizenship:

Mr. Smithline is a United States citizen.

Centrecourt is organized and existing in Delaware.

CAMOFI is organized and existing in the Cayman Islands.

(d) Title of Class of Securities:

Common Stock, \$0.001 par value per share.

(e) CUSIP Number:

74373-F-100

Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) Investment company registered under Section 8 of the Investment Company Act.
- (e) Investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E).
- (f) Employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F).
- (g) Parent holding company, in accordance with Sec. 240.13d-1(b)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j) Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Sec. 240.13d-1(c), check this box .

Item 4. Ownership:

(a) Amount Beneficially Owned:

Mr. Smithline: 1,117,333* shares of Common Stock comprised of (i) 117,333 shares of Common Stock held by CAMOFI, and (ii) 1,000,000 shares of Common Stock issuable within 60 days upon the exercise of a warrant held by CAMOFI. Mr. Smithline is a director of CAMOFI.

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

Centrecourt: 1,117,333* shares of Common Stock comprised of (i) 117,333 shares of Common Stock held by CAMOFI, and (ii) 1,000,000 shares of Common Stock issuable within 60 days upon the exercise of a warrant held by CAMOFI. Centrecourt is the investment manager of CAMOFI.

CAMOFI: 1,117,333* shares of Common Stock comprised of (i) 117,333 shares of Common Stock held by CAMOFI, and (ii) 1,000,000 shares of Common Stock issuable within 60 days upon the exercise of a warrant held by CAMOFI.

- | | | |
|---|----------------|------------|
| (b) Percent of Class. | Mr. Smithline: | 2.23%* |
| | Centrecourt: | 2.23%* |
| | CAMOFI: | 2.23%* |
| (c) Number of shares as to which each such person has: | | |
| (i) sole power to vote or to direct the vote: | Mr. Smithline: | 1,117,333* |
| | Centrecourt: | 1,117,333* |
| | CAMOFI: | 1,117,333* |
| (ii) shared power to vote or to direct the vote: | Mr. Smithline: | 0 |
| | Centrecourt: | 0 |
| | CAMOFI: | 0 |
| (iii) sole power to dispose or to direct the disposition of: | Mr. Smithline: | 1,117,333* |
| | Centrecourt: | 1,117,333* |
| | CAMOFI: | 1,117,333* |
| (iv) shared power to dispose or to direct the disposition of: | Mr. Smithline: | 0 |
| | Centrecourt: | 0 |
| | CAMOFI: | 0 |

*The numbers set forth above include 1,000,000 shares of Common Stock issuable within 60 days upon the exercise of a warrant which contains a provision which would prohibit the holder thereof from exercising such warrant to the extent that upon such exercise, such holder, together with its affiliates, would beneficially hold more than 9.99% of the total number of shares of Common Stock then issued and outstanding (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended), unless such holder shall have provided the issuer with 61 days' notice of the holder's waiver of such provisions. Even if such warrant is exercised in full, the Reporting Persons would beneficially own, at most, 2.23% of the issuer's issued and outstanding Common Stock as of the date hereof. Accordingly, such warrant is exercisable in full as of the date hereof. However, the Reporting Persons disclaim beneficial ownership of such securities, and Mr. Smithline and Centrecourt disclaim beneficial ownership of all securities covered by this statement.

The percentages used herein are based upon the securities held by the Reporting Persons as of February 1, 2008, and the number of the issuer's shares

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

of Common Stock issued and outstanding as of November 26, 2007, as reported in the issuer's Amendment No. 2 to Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on January 28, 2008.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

See Item 4(a) above, which is incorporated by reference herein.

Item 8. Identification and Classification of Members of the Group.

The Reporting Persons may be deemed to constitute a group with one another pursuant to Section 13 of the Securities Exchange Act of 1934. The Reporting Persons do not affirm the existence of such a group.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 4, 2008

/s/ Richard Smithline

Richard Smithline

Centrecourt Asset Management LLC

By: /s/ Richard Smithline

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

Name: Richard Smithline
Title: Managing Member

CAMOFI Master LDC

By: /s/ Richard Smithline

Name: Richard Smithline
Title: Director

Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001).

EXHIBIT A

AGREEMENT

JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree jointly to prepare and file with regulatory
authorities an Amendment No. 4 to Schedule 13G and any amendments thereto
reporting each of the undersigned's ownership of securities of Provectus
Pharmaceuticals, Inc. and hereby affirm that such Amendment No. 4 to Schedule
13G is being filed on behalf of each of the undersigned.

Date: February 4, 2008

/s/ Richard Smithline

Richard Smithline

Centrecourt Asset Management LLC

By: /s/ Richard Smithline

Name: Richard Smithline
Title: Managing Member

CAMOFI Master LDC

By: /s/ Richard Smithline

Name: Richard Smithline
Title: Director